©The Author(s) 2025.
World J Crit Care Med. Dec 9, 2025; 14(4): 108744
Published online Dec 9, 2025. doi: 10.5492/wjccm.v14.i4.108744
Published online Dec 9, 2025. doi: 10.5492/wjccm.v14.i4.108744
Table 4 Magnesium disorders correction
| Disorder | Treatment | Dose/route | Notes |
| Hypomagnesemia | IV magnesium sulfate | 1-2 g IV over 1 hour, then 4-8 g IV over 12-24 h; in emergencies (e.g., torsades) 1-2 g IV over 15 min | Use central access for prolonged high-dose infusion; monitor serum Mg 2 h after start of infusion due to renal losses; faster infusion (e.g., in TdP) may be warranted |
| Oral magnesium | Magnesium oxide or lactate 300-600 mg (12-25 mmol) PO 2-4 times daily | Use in mild, asymptomatic cases with intact GI tract; bioavailability limited; avoid if significant GI intolerance | |
| Hypermagnesemia | Remove exogenous sources | Discontinue all magnesium-containing meds/infusions | Necessary first step; review all sources (IV fluids, TPN additives, supplements) |
| Calcium gluconate | 1-2 g IV over 5-10 min | Stabilizes cardiac membrane in severe elevations (> 4 mg/dL) or ECG changes; repeat PRN | |
| Loop diuretics + IV fluids | Furosemide 20-40 mg IV once, with isotonic saline bolus | Promotes renal Mg excretion; ensure adequate volume status; monitor electrolytes and renal function | |
| Hemodialysis | Standard-dialyze against low-Mg/zero-Mg bath | Reserved for refractory or life-threatening hypermagnesemia in renal failure |
- Citation: Mejia Herrera F, Marino L, Bilotta F. Hydroelectrolytic syndromes in neuroanesthesia and neurocritical care. World J Crit Care Med 2025; 14(4): 108744
- URL: https://www.wjgnet.com/2220-3141/full/v14/i4/108744.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v14.i4.108744